BMS gets EC approval for Opdivo, Yervoy combo for treatment of metastatic NSCLC

This article was originally published here

The combination of Opdivo plus Yervoy with two cycles of chemotherapy is the first dual immunotherapy-based treatment option approved for patients in the European Union (EU) with this

The post BMS gets EC approval for Opdivo, Yervoy combo for treatment of metastatic NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply